T1	Participants 38 96	opioid use during prescription opioid dependence treatment
T2	Participants 559 709	participants with prescription opioid dependence who received 12 weeks of buprenorphine-naloxone and counseling in a multi-site clinical trial (N=353)
T3	Participants 468 521	outpatient treatment of prescription opioid addiction
T4	Participants 1548 1594	individuals with prescription opioid addiction
T5	Participants 1677 1702	prescription opioid users
